Intravitreal ranibizumab mod aldersrelateret makuladegeneration

Torben Lykke Sørensen*, Henrik Kemp

*Corresponding author af dette arbejde

Publikation: Bidrag til tidsskriftArtikelForskningpeer review


Introduction: Ranibizumab has improved visual prognosis for patients with age-related macula degeneration (ARMD) complicated with choroidal neovascularisation. We evaluated the results of all our patients within a two-year period. Material and methods: A total of 647 eyes have so far been treated. In all 2,735 injections have been performed. Results: Ranibizumab initially increased significantly the best corrected visual acuity from 0.29 to 0.35 (p < 0,001), but after six and 12 months visual acuity stabilized (p = 0.1). We found a positive correlation between initial visual acuity and final visual acuity (p < 0.001). There was a negative correlation between age and final visual acuity (p < 0.001). Complications were rare: one got cataract, we observed a retinal detachment and one choroidal detachment. Other complications were rare and mild. Dsicussion: Ranibizumab improves visual prognosis in exudative ARMD. Intravitreal injections are safe and complications are rare.

Bidragets oversatte titelIntravitreal ranibizumab for age-related macular degeneration
TidsskriftUgeskrift for laeger
Udgave nummer22
StatusUdgivet - 1 maj 2010


Udforsk hvilke forskningsemner 'Intravitreal ranibizumab mod aldersrelateret makuladegeneration' indeholder.